{"filing":{"accession_number":"0001140361-26-031540","cik":"0001708688","ticker":"IFRX","company_name":"InflaRx N.V.","form":"6-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"ef20079015_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1708688/000114036126031540/ef20079015_6k.htm"},"events":[{"id":24509,"run_id":22212,"accession_number":"0001140361-26-031540","anchor_item_number":"EX-99.3","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This exhibit is a press release announcing InflaRx's second quarter 2026 financial results, including unaudited consolidated statements of operations, financial position, changes in shareholders' equity, and cash flows for the six months ended June 30, 2026. The document explicitly states \"InflaRx Reports Second Quarter 2026 Results\" and includes detailed financial highlights, net loss figures (€16.2 million for H1 2026), and cash position (€158.4 million). This is a discrete earnings announcement, not a periodic financial report filing itself.","company_name":"InflaRx N.V.","ticker":"IFRX","filing_date":"2026-08-06","form":"6-K","submitted_at":null,"items":[{"id":25091,"accession_number":"0001140361-26-031540","item_number":"EX-99.3","item_title":"ef20079015_ex99-3.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This exhibit is a press release announcing InflaRx's second quarter 2026 financial results, including unaudited consolidated statements of operations, financial position, changes in shareholders' equity, and cash flows for the six months ended June 30, 2026. The document explicitly states \"InflaRx Reports Second Quarter 2026 Results\" and includes detailed financial highlights, net loss figures (€16.2 million for H1 2026), and cash position (€158.4 million). This is a discrete earnings announcement, not a periodic financial report filing itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:01:03.420740+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25089,"accession_number":"0001140361-26-031540","item_number":"EX-99.1","item_title":"ef20079015_ex99-1.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":false,"confidence":0.95,"reasoning":"This exhibit is an unaudited condensed consolidated interim financial report for the six months ended June 30, 2026, prepared under IAS 34 Interim Financial Reporting. The document explicitly states it comprises \"unaudited condensed consolidated financial statements\" covering a six-month period and includes all standard interim financial statements (statements of operations, financial position, changes in equity, and cash flows). This is a periodic interim report itself, not a discrete event or earnings press release announcing results.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:01:03.420740+00:00","company_name":"InflaRx N.V.","ticker":"IFRX","filing_date":"2026-08-06"},{"id":25090,"accession_number":"0001140361-26-031540","item_number":"EX-99.2","item_title":"ef20079015_ex99-2.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":false,"confidence":0.95,"reasoning":"This exhibit is a Management's Discussion and Analysis (MD\u0026A) accompanying unaudited interim condensed consolidated financial statements for the six months ended June 30, 2026. The document explicitly states it is designed to be read \"together with our unaudited interim condensed consolidated financial statements\" and references \"Exhibit 99.1 to the report on Form 6-K.\" This is a periodic interim financial report, not a discrete event disclosure. MD\u0026A is a standard component of interim financial reporting and should be classified as the periodic report itself, not as an earnings release or other event.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:01:03.420740+00:00","company_name":"InflaRx N.V.","ticker":"IFRX","filing_date":"2026-08-06"},{"id":25091,"accession_number":"0001140361-26-031540","item_number":"EX-99.3","item_title":"ef20079015_ex99-3.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This exhibit is a press release announcing InflaRx's second quarter 2026 financial results, including unaudited consolidated statements of operations, financial position, changes in shareholders' equity, and cash flows for the six months ended June 30, 2026. The document explicitly states \"InflaRx Reports Second Quarter 2026 Results\" and includes detailed financial highlights, net loss figures (€16.2 million for H1 2026), and cash position (€158.4 million). This is a discrete earnings announcement, not a periodic financial report filing itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:01:03.420740+00:00","company_name":"InflaRx N.V.","ticker":"IFRX","filing_date":"2026-08-06"}]}